Roquette Acquires Itacel
Roquette has completed its previously announced acquisition of Itacel, an excipient division of Blanver.
On Sept. 1, 2017, Roquette, a French biopharmaceutical company specializing in plant-based excipients, completed the previously announced acquisition of Itacel. Itacel is an excipient division of Blanver, a Brazilian multinational company specializing in the development, manufacture, and commercialization of raw materials and drugs.
The acquisition is part of a series of investments made by Roquette to position itself globally, according to the company. Financial details of the closing are unpublicized.
Source: Roquette
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Telix Enters Agreement with ImaginAb to Purchase Next-Gen Therapeutic Candidates
Published: January 13th 2025 | Updated: January 13th 2025The transaction adds a pipeline of early-stage drug candidates against high-value targets to Telix’s portfolio, along with other novel targets currently in the discovery stage.
